{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:07:08Z","timestamp":1792919228734,"version":"4.5.0"},"reference-count":166,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SS is a chronic, autoimmune disease of unknown aetiology for which there is no known curative treatment. Although dryness of the eyes and mouth are the classically described features, patients often experience drying of other mucosal surfaces and systemic manifestations, including fatigue and arthralgia. There is an association with other autoimmune diseases, especially thyroid disease, coeliac disease and primary biliary cholangitis. Systemic features may affect up to 70% and include inflammatory arthritis, skin involvement, haematological abnormalities, neuropathies, interstitial lung disease and a 5\u201310% lifetime risk of B cell lymphoma. Treatment should aim to empower patients to manage their condition; conserve, replace and stimulate secretions; prevent damage; and suppress underlying systemic disease activity.<\/jats:p>","DOI":"10.1093\/rheumatology\/key363","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T06:58:46Z","timestamp":1541055526000},"page":"2574-2587","source":"Crossref","is-referenced-by-count":18,"title":["How to treat Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1093","volume":"60","author":[{"given":"Elizabeth J","family":"Price","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust, Swindon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan N","family":"Baer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2021061821294781800_key363-B1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/annrheumdis-2015-207499","article-title":"Review of salivary gland histopathology in primary Sj\u00f6gren\u2019s syndrome with a focus on its potential as a clinical trials biomarker","volume":"74","author":"Fisher","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine"},{"key":"2021061821294781800_key363-B3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.adaj.2015.11.008","article-title":"Clinical practice guidelines for oral management of Sj\u00f6gren disease: dental caries prevention","volume":"147","author":"Zero","year":"2016","journal-title":"J Am Dent Assoc"},{"key":"2021061821294781800_key363-B5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtos.2014.12.001","article-title":"Clinical guidelines for management of dry eye associated with Sj\u00f6gren disease","volume":"13","author":"Foulks","year":"2015","journal-title":"Ocul Surf"},{"key":"2021061821294781800_key363-B6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for Sjogren\u2019s disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2021061821294781800_key363-B7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sjogren\u2019s: use of biologics, management of fatigue and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2021061821294781800_key363-B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14397595.2018.1438093","article-title":"Clinical practice guideline for Sjogren\u2019s syndrome 2017","volume":"28","author":"Sumida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2021061821294781800_key363-B9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2021061821294781800_key363-B10","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s Syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","article-title":"International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren\u2019s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021061821294781800_key363-B12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021061821294781800_key363-B13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5271\/sjweh.989","article-title":"Changes in ocular and nasal signs and symptoms among air crew in relation to air humidification on intercontinental flights","volume":"32","author":"Norb\u00e4ck","year":"2006","journal-title":"Scand J Work Environ Health"},{"key":"2021061821294781800_key363-B14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hed.20419","article-title":"Optimal nocturnal humidification for xerostomia","volume":"28","author":"Hay","year":"2006","journal-title":"Head Neck"},{"key":"2021061821294781800_key363-B15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1755-3768.2011.02196.x","article-title":"A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients","volume":"89","author":"Brignole-Baudouin","year":"2011","journal-title":"Acta Opthalmol"},{"key":"2021061821294781800_key363-B16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICO.0b013e3181f22e03","article-title":"Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye","volume":"30","author":"Wojtowicz","year":"2011","journal-title":"Cornea"},{"key":"2021061821294781800_key363-B17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"n-3 fatty acid supplementation for the treatment of dry eye disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N Engl J Med"},{"key":"2021061821294781800_key363-B18","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3945\/jn.109.118901","article-title":"Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye","volume":"140","author":"Larmo","year":"2010","journal-title":"J Nutr"},{"key":"2021061821294781800_key363-B19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0b013e32801494e3","article-title":"The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjogren\u2019s syndrome","volume":"19","author":"Strombeck","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"2021061821294781800_key363-B20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kev227","article-title":"A systematic review of non-pharmacological interventions for primary Sjogren\u2019s syndrome","volume":"54","author":"Hackett","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"2021061821294781800_key363-B22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02853166","article-title":"Effects of common ophthalmic preservatives on ocular health","volume":"18","author":"Noecker","year":"2001","journal-title":"Adv Ther"},{"key":"2021061821294781800_key363-B23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0181-5512(07)89605-7","article-title":"Tear lipid layer thickness and ocular comfort with a novel device in dry eye patients with and without Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Spiteri","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"2021061821294781800_key363-B24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ophtha.2015.10.062","article-title":"Oral antibiotics for meibomian gland-related ocular surface disease: a report by the American Academy of Ophthalmology","volume":"123","author":"Wladis","year":"2016","journal-title":"Ophthalmology"},{"key":"2021061821294781800_key363-B25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","article-title":"Topical azithromycin therapy of meibomian gland dysfunction: clinical response and lipid alterations","volume":"29","author":"Foulks","year":"2010","journal-title":"Cornea"},{"key":"2021061821294781800_key363-B26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","article-title":"Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis","volume":"29","author":"Haque","year":"2010","journal-title":"Cornea"},{"key":"2021061821294781800_key363-B27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00106-013-2736-x","article-title":"Liposomal local therapy as treatment for sicca symptoms in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"61","author":"Hofauer","year":"2013","journal-title":"HNO"},{"key":"2021061821294781800_key363-B28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00003226-199405000-00001","article-title":"Spectacle side panels and moist inserts for the treatment of dry-eye patients","volume":"13","author":"Tsubota","year":"1994","journal-title":"Cornea"},{"key":"2021061821294781800_key363-B29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3109\/02713683.2014.932389","article-title":"Specialized moisture retention eyewear for evaporative dry eye","volume":"40","author":"Waduthantri","year":"2015","journal-title":"Curr Eye Res"},{"key":"2021061821294781800_key363-B30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/15569527.2013.832688","article-title":"Effects of chronic smoking on central corneal thickness, endothelial cell, and dry eye parameters","volume":"33","author":"Sayin","year":"2014","journal-title":"Cutan Ocul Toxicol"},{"key":"2021061821294781800_key363-B31","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","article-title":"Punctal plugs versus artificial tears for treating primary Sj\u00f6gren\u2019s syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function","volume":"33","author":"Qiu","year":"2013","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B32","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00296-010-1527-x","article-title":"Clinical efficacy of the SmartPlugTM in the treatment of primary Sjogren\u2019s syndrome with keratoconjunctivitis sicca: one-year follow-up study","volume":"31","author":"Egrilmez","year":"2011","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bjo.83.4.390","article-title":"Treatment of dry eye by autologous serum application in Sj\u00f6gren\u2019s syndrome","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"2021061821294781800_key363-B34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"2021061821294781800_key363-B35","doi-asserted-by":"crossref","DOI":"10.1038\/eye.2017.209","article-title":"The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report","author":"Rauz","year":"2017","journal-title":"Eye"},{"key":"2021061821294781800_key363-B36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5301\/ejo.5000229","article-title":"Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sj\u00f6gren syndrome","volume":"23","author":"Aragona","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"2021061821294781800_key363-B37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","article-title":"Ocular effects of topical and systemic steroids","volume":"10","author":"Renfro","year":"1992","journal-title":"Dermatol Clin"},{"key":"2021061821294781800_key363-B38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10792-014-9901-4","article-title":"The efficacy of topical 0.05% cyclosporine A in patients with dry eye disease associated with Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Devec\u0131","year":"2014","journal-title":"Int Ophthalmol"},{"key":"2021061821294781800_key363-B39","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/ICO.0b013e31812f6782","article-title":"Management of ocular surface inflammation in Sj\u00f6gren syndrome","volume":"26","author":"Hyon","year":"2007","journal-title":"Cornea"},{"key":"2021061821294781800_key363-B40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"2021061821294781800_key363-B41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/14740338.6.1.33","article-title":"Is it safe to use topical NSAIDs for corneal sensitivity in Sj\u00f6gren\u2019s syndrome patients?","volume":"6","author":"Aragona","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"2021061821294781800_key363-B42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj\u00f6gren\u2019s syndrome patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye"},{"key":"2021061821294781800_key363-B43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bjo.52.4.310","article-title":"Acetylcysteine in kerato-conjunctivitis sicca","volume":"52","author":"Absolon","year":"1968","journal-title":"Br J Ophthalmol"},{"key":"2021061821294781800_key363-B44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/jop.2010.0001","article-title":"Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction","volume":"26","author":"Akyol-Salman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"2021061821294781800_key363-B45","first-page":"1842","article-title":"Botulinum toxin increases tearing in patients with Sjogren\u2019s syndrome: a preliminary report","volume":"24","author":"Spiera","year":"1997","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000131089","article-title":"Eyelid botulinum toxin injections for the dry eye","volume":"41","author":"Sahlin","year":"2008","journal-title":"Dev Ophthalmol"},{"key":"2021061821294781800_key363-B47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajo.2015.11.034","article-title":"The use of the esclera scleral contact lens in the treatment of moderate to severe dry eye disease","volume":"163","author":"La Porta Weber","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2021061821294781800_key363-B48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ICU.0000000000000171","article-title":"Scleral lens use in dry eye syndrome","volume":"26","author":"Bavinger","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"2021061821294781800_key363-B49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.ICL.0000152492.98553.8D","article-title":"Fluid-ventilated, gas-permeable scleral contact lens is an effective option for managing severe ocular surface disease and many corneal disorders that would otherwise require penetrating keratoplasty","volume":"31","author":"Rosenthal","year":"2005","journal-title":"Eye Contact Lens"},{"key":"2021061821294781800_key363-B50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10561-009-9128-1","article-title":"Serum eye drops, amniotic membrane and limbal epithelial stem cells\u2014tools in the treatment of ocular surface disease","volume":"11","author":"Rauz","year":"2010","journal-title":"Cell Tissue Bank"},{"key":"2021061821294781800_key363-B51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/000163501750266684","article-title":"Dental caries and dental health behavior of patients with primary Sj\u00f6gren syndrome","volume":"59","author":"Christensen","year":"2001","journal-title":"Acta Odontol Scand"},{"key":"2021061821294781800_key363-B52","first-page":"1007","article-title":"Microflora in oral ecosystems in primary Sjogren\u2019s syndrome","volume":"28","author":"Almstahl","year":"2001","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B53","first-page":"23","article-title":"Effect of chlorhexidine gluconate mouth wash on the plaque microflora in children using intra oral appliances","volume":"20","author":"Amitha","year":"1995","journal-title":"J Clin Pediatr Dent"},{"key":"2021061821294781800_key363-B54","first-page":"65","article-title":"Xylitol chewing gum and dental caries","volume":"45","author":"Tanzer","year":"1995","journal-title":"Int Dent J"},{"key":"2021061821294781800_key363-B55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archpediatrics.2009.77","article-title":"Xylitol pediatric topical oral syrup to prevent dental caries: a double-blind randomized clinical trial of efficacy","volume":"163","author":"Milgrom","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2021061821294781800_key363-B56","first-page":"Cd010743","article-title":"Xylitol-containing products for preventing dental caries in children and adults","author":"Riley","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021061821294781800_key363-B57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"2021061821294781800_key363-B58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0929-6646(09)60266-7","article-title":"Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sj\u00f6gren\u2019s syndrome in Taiwan\u2014a double-blind, placebo-controlled trial","volume":"105","author":"Wu","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"2021061821294781800_key363-B59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0030-4220(91)90491-T","article-title":"Effects of pilocarpine on salivary flow in patients with Sj\u00f6gren\u2019s syndrome","volume":"72","author":"Rhodus","year":"1991","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"2021061821294781800_key363-B60","first-page":"705","article-title":"Candida albicans levels in patients with Sjogren\u2019s syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study","volume":"29","author":"Rhodus","year":"1998","journal-title":"Quintessence Int (Berlin)"},{"key":"2021061821294781800_key363-B61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjo.2005.078865","article-title":"Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren\u2019s syndrome","volume":"90","author":"Aragona","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"2021061821294781800_key363-B62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0025-7753(04)75314-2","article-title":"Usefulness of oral pilocarpine therapy in the treatment of xerostomia and xerophthalmia in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"122","author":"Solans","year":"2004","journal-title":"Med Clin"},{"key":"2021061821294781800_key363-B63","first-page":"Cd009327","article-title":"Autologous serum eye drops for dry eye","volume":"8)","author":"Pan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2021061821294781800_key363-B64","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B65","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ophtha.2010.12.016","article-title":"Treatment of Sjogren\u2019s syndrome-associated dry eye: an evidence-based review","volume":"118","author":"Akpek","year":"2011","journal-title":"Ophthalmology"},{"key":"2021061821294781800_key363-B66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/s10165-010-0313-7","article-title":"Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjogren\u2019s syndrome","volume":"20","author":"Tomiita","year":"2010","journal-title":"Mod Rheumatol"},{"key":"2021061821294781800_key363-B67"},{"key":"2021061821294781800_key363-B68","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/clim.2001.5128","article-title":"Use of muscarinic agonists in the treatment of Sjogren\u2019s syndrome","volume":"101","author":"Fox","year":"2001","journal-title":"Clin Immunol (Orlando)"},{"key":"2021061821294781800_key363-B70","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021061821294781800_key363-B71","first-page":"300","article-title":"Prevalence, density, and manifestations of oral Candida albicans in patients with Sjogren\u2019s syndrome","volume":"26","author":"Rhodus","year":"1997","journal-title":"J Otolaryngol"},{"key":"2021061821294781800_key363-B72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1601-0825.2007.01368.x","article-title":"Sjogren\u2019s syndrome sufferers have increased oral yeast levels despite regular dental care","volume":"14","author":"Leung","year":"2008","journal-title":"Oral Dis"},{"key":"2021061821294781800_key363-B73","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0030-4220(89)90218-1","article-title":"Oral candidiasis in Sjogren\u2019s syndrome: prevalence, clinical correlations, and treatment","volume":"68","author":"Hernandez","year":"1989","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"2021061821294781800_key363-B74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1148\/rg.263055024","article-title":"US of the major salivary glands: anatomy and spatial relationships, pathologic conditions, and pitfalls","volume":"26","author":"Bialek","year":"2006","journal-title":"Radiographics"},{"key":"2021061821294781800_key363-B75","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jcms.2015.06.036","article-title":"Endoscopic management of salivary gland obstructive diseases in patients with Sj\u00f6gren\u2019s syndrome","volume":"43","author":"De Luca","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"2021061821294781800_key363-B76","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1378\/chest.70.4.506","article-title":"S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction","volume":"70","author":"Edwards","year":"1976","journal-title":"Chest"},{"key":"2021061821294781800_key363-B77","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/keu522","article-title":"The impact of primary Sj\u00f6gren\u2019s syndrome on female sexual function","volume":"54","author":"van Nimwegen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B78","first-page":"912","article-title":"Sjogren\u2019s syndrome: clinical, cytological, histological and colposcopic aspects in women","volume":"15","author":"Capriello","year":"1988","journal-title":"Clin Exp Obstet Gynecol"},{"key":"2021061821294781800_key363-B79","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1701-2163(16)30662-4","article-title":"The detection and management of vaginal atrophy","volume":"26","author":"Johnston","year":"2004","journal-title":"J Obstet Gynaecol Can"},{"key":"2021061821294781800_key363-B80","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00404-013-3068-5","article-title":"Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?","volume":"288","author":"Stute","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"2021061821294781800_key363-B81","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jsm.12125","article-title":"Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial","volume":"10","author":"Chen","year":"2013","journal-title":"J Sex Med"},{"key":"2021061821294781800_key363-B82","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren\u2019s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B83","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3899\/jrheum.090942","article-title":"Comorbidities in patients with primary Sjogren\u2019s syndrome: a registry-based case-control study","volume":"37","author":"Kang","year":"2010","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(94)80007-3","article-title":"Autoimmune liver disease in patients with primary Sjogren\u2019s syndrome","volume":"20","author":"Lindgren","year":"1994","journal-title":"J Hepatol"},{"key":"2021061821294781800_key363-B85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00296-003-0360-x","article-title":"Coeliac disease in Sjogren\u2019s syndrome\u2014a study of 111 Hungarian patients","volume":"24","author":"Szodoray","year":"2004","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.reuma.2015.09.003","article-title":"Sjogren\u2019s syndrome-associated interstitial lung disease: a multicenter study","volume":"12","author":"Reina","year":"2016","journal-title":"Reumatol Clin"},{"key":"2021061821294781800_key363-B87","doi-asserted-by":"crossref","first-page":"e73774","DOI":"10.1371\/journal.pone.0073774","article-title":"Prognostic factors in interstitial lung disease associated with primary Sjogren\u2019s syndrome: a retrospective analysis of 33 pathologically-proven cases","volume":"8","author":"Enomoto","year":"2013","journal-title":"PLoS One"},{"key":"2021061821294781800_key363-B88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sjogren\u2019s syndrome","volume":"16","author":"Roca","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021061821294781800_key363-B89","first-page":"1539","article-title":"[Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjogren syndrome]","volume":"48","author":"Hattori","year":"2007","journal-title":"Rinsho Ketsueki"},{"key":"2021061821294781800_key363-B90","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archneur.58.5.815","article-title":"Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide","volume":"58","author":"Williams","year":"2001","journal-title":"Arch Neurol"},{"key":"2021061821294781800_key363-B91","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1212\/WNL.52.2.386","article-title":"Improvement of myelopathy in Sjogren\u2019s syndrome with chlorambucil and prednisone therapy","volume":"52","author":"Wright","year":"1999","journal-title":"Neurology"},{"key":"2021061821294781800_key363-B92","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","article-title":"Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren\u2019s syndrome","volume":"38","author":"Miyawaki","year":"1999","journal-title":"Intern Med"},{"key":"2021061821294781800_key363-B93","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren\u2019s syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B94","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sjogren\u2019s syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"2021061821294781800_key363-B95","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","article-title":"Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: its effect on salivary and serum inflammatory markers","volume":"58","author":"Tishler","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B97","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"2021061821294781800_key363-B98","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/rheumatology\/keh554","article-title":"BSR guidelines on standards of care for persons with rheumatoid arthritis","volume":"44","author":"Kennedy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B99","first-page":"555","article-title":"Methotrexate in primary Sjogren\u2019s syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2021061821294781800_key363-B100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/s10165-011-0440-9","article-title":"Long-term remission of pulmonary veno-occlusive disease associated with primary Sjogren\u2019s syndrome following immunosuppressive therapy","volume":"21","author":"Naniwa","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2021061821294781800_key363-B101","doi-asserted-by":"crossref","first-page":"875; author reply 6","DOI":"10.1001\/archneur.59.5.875","article-title":"Treatment of Sjogren syndrome myelopathy with azathioprine and steroids","volume":"59","author":"Hawley","year":"2002","journal-title":"Arch Neurol"},{"key":"2021061821294781800_key363-B102","first-page":"482","article-title":"Autoimmune hemolytic anemia preceding Sjogren\u2019s syndrome","volume":"10","author":"Schattner","year":"1983","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B103","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren\u2019s syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B104","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2021061821294781800_key363-B105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1590\/S0482-50042012000200013","article-title":"Mycophenolate mofetil in primary Sjogren\u2019s syndrome: a treatment option for agranulocytosis","volume":"52","author":"Fialho","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"2021061821294781800_key363-B106","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2021061821294781800_key363-B107","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00296-016-3463-x","article-title":"Dramatic improvement of anti-SS-A\/Ro-associated interstitial lung disease after immunosuppressive treatment","volume":"36","author":"Paola","year":"2016","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jbspin.2014.12.007","article-title":"Sjogren\u2019s syndrome complicated by interstitial cystitis: a case series and literature review","volume":"82","author":"Darrieutort-Laffite","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2021061821294781800_key363-B109","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1346-8138.12475","article-title":"Annular erythema of Sjogren\u2019s syndrome treated successfully with low-dose cyclosporine","volume":"41","author":"Nobeyama","year":"2014","journal-title":"J Dermatol"},{"key":"2021061821294781800_key363-B110","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00296-010-1782-x","article-title":"Interstitial cystitis: a rare manifestation of primary Sjogren\u2019s syndrome, successfully treated with low dose cyclosporine","volume":"32","author":"Emmungil","year":"2012","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B111","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/s10165-003-0242-9","article-title":"Successful treatment of pure red cell aplasia and autoimmune cytopenia with cyclosporine and prednisolone in a patient with Sjogren\u2019s syndrome","volume":"13","author":"Shiratsuchi","year":"2003","journal-title":"Mod Rheumatol"},{"key":"2021061821294781800_key363-B112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF01452266","article-title":"Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjogren\u2019s syndrome","volume":"17","author":"Ogasawara","year":"1998","journal-title":"Clin Rheumatol"},{"key":"2021061821294781800_key363-B113","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/annrheumdis-2015-eular.2806","article-title":"THU0399 effectiveness and safety of low-dose cyclosporine a in patients with primary Sj\u00f6gren\u2019s syndrome (PSS) with articular involvement \u2013 results of a pilot study","volume":"74","author":"Kedor","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B114","first-page":"709","article-title":"Myelopathies secondary to Sjogren\u2019s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids","volume":"33","author":"de Seze","year":"2006","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5114\/aoms.2012.30788","article-title":"Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjogren\u2019s syndrome","volume":"8","author":"Lin","year":"2012","journal-title":"Arch Med Sci"},{"key":"2021061821294781800_key363-B116","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5414\/CN107283","article-title":"Type III membranoproliferative glomerulonephritis in a patient with primary Sjogren\u2019s syndrome","volume":"79","author":"Sun","year":"2013","journal-title":"Clin Nephrol"},{"key":"2021061821294781800_key363-B117","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/03009740701867323","article-title":"Sjogren\u2019s syndrome \u2013 not just Sicca: renal involvement in Sjogren\u2019s syndrome","volume":"37","author":"Kaufman","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"2021061821294781800_key363-B118","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y","article-title":"Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases","volume":"41","author":"Schnabel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B119","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B120","first-page":"88","article-title":"[Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjogren\u2019s disease: preliminary data]","volume":"84","author":"Logvinenko","year":"2012","journal-title":"Ter Arkh"},{"key":"2021061821294781800_key363-B121","first-page":"210","article-title":"[Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjogren syndrome]","volume":"52","author":"Iwabuchi","year":"2011","journal-title":"Rinsho Ketsueki"},{"key":"2021061821294781800_key363-B122","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B123","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00296-007-0396-4","article-title":"Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren\u2019s syndrome","volume":"28","author":"Seve","year":"2007","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B124","first-page":"37","article-title":"[The efficacy and safety of low-dose rituximab in treatment of primary Sjogren\u2019s syndrome with thrombocytopenia]","volume":"51","author":"Zhou","year":"2012","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2021061821294781800_key363-B125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"2021061821294781800_key363-B126","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren\u2019s syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B127","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren\u2019s syndrome: a retrospective clinical study","volume":"38","author":"Pollard","year":"2011","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0961203307078201","article-title":"Successful treatment of refractory neuroSjogren with Rituximab","volume":"16","author":"Yamout","year":"2007","journal-title":"Lupus"},{"key":"2021061821294781800_key363-B129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"key":"2021061821294781800_key363-B130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021061821294781800_key363-B131","first-page":"s10","article-title":"Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome","volume":"67","author":"Bowman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021061821294781800_key363-B132","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B133","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sjogren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2021061821294781800_key363-B134","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B135","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren\u2019s syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B136","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren\u2019s syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B137","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren\u2019s syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"2021061821294781800_key363-B138","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B139","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B140","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren\u2019s syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021061821294781800_key363-B141","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2008.12.018","article-title":"Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren\u2019s syndrome","volume":"279","author":"Morozumi","year":"2009","journal-title":"J Neurol Sci"},{"key":"2021061821294781800_key363-B142","first-page":"457","article-title":"Myositis in primary Sjogren\u2019s syndrome: data from a multicentre cohort","volume":"33","author":"Colafrancesco","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2021061821294781800_key363-B143","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s10067-003-0852-9","article-title":"Hypergammaglobulinemic purpura in two sisters with Sjogren\u2019s syndrome responding to colchicine treatment","volume":"23","author":"Habib","year":"2004","journal-title":"Clin Rheumatol"},{"key":"2021061821294781800_key363-B144","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archderm.144.6.815","article-title":"Granulomatous panniculitis associated with Sjogren syndrome","volume":"144","author":"Chandrupatla","year":"2008","journal-title":"Arch Dermatol"},{"key":"2021061821294781800_key363-B145","first-page":"25","article-title":"[Recurrent acute idiopathic pericarditis: rheumatologic therapy, autoantibodies and long term outcome]","volume":"59","author":"Brambilla","year":"2007","journal-title":"Reumatismo"},{"key":"2021061821294781800_key363-B146","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.53.9.569","article-title":"Obstetric and gynaecological profile in patients with primary Sjogren\u2019s syndrome","volume":"53","author":"Skopouli","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B147","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/rheumatology\/38.12.1228","article-title":"Recurrent pregnancy loss and autoantibody profile in autoimmune diseases","volume":"38","author":"Mavragani","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B148","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/03009742.2016.1158312","article-title":"Pregnancy and primary Sjogren\u2019s syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies","volume":"46","author":"Ballester","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"2021061821294781800_key363-B149","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/mpd.2000.109108","article-title":"Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry","volume":"137","author":"Neiman","year":"2000","journal-title":"J Pediatr"},{"key":"2021061821294781800_key363-B150","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C","article-title":"Risk of congenital complete heart block in newborns of mothers with anti-Ro\/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women","volume":"44","author":"Brucato","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B151","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/art.20126","article-title":"Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA\/Ro 52-kd antibodies","volume":"50","author":"Sonesson","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B152","doi-asserted-by":"crossref","first-page":"544","DOI":"10.7326\/0003-4819-120-7-199404010-00003","article-title":"Autoantibody-associated congenital heart block: outcome in mothers and children","volume":"120","author":"Waltuck","year":"1994","journal-title":"Ann Inter Med"},{"key":"2021061821294781800_key363-B153","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1440-1754.1993.tb03026.x","article-title":"Liver disease in association with neonatal lupus erythematosus","volume":"29","author":"Evans","year":"1993","journal-title":"J Paediatr Child Health"},{"key":"2021061821294781800_key363-B154","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"2021061821294781800_key363-B155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/OGX.0b013e31815e8731","article-title":"Aspirin and reproductive outcomes","volume":"63","author":"James","year":"2008","journal-title":"Obstet Gynecol Surv"},{"key":"2021061821294781800_key363-B156","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.autrev.2004.11.009","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases","volume":"4","author":"Costedoat-Chalumeau","year":"2005","journal-title":"Review of the literature. Autoimmun Rev"},{"key":"2021061821294781800_key363-B157","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021061821294781800_key363-B158","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014Part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology. Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B159","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B160","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","article-title":"Incidence of cancer in a cohort of patients with primary Sjogren\u2019s syndrome","volume":"45","author":"Lazarus","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821294781800_key363-B161","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine"},{"key":"2021061821294781800_key363-B162","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren\u2019s syndrome","volume":"41","author":"Solans-Laque","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2021061821294781800_key363-B163","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sjogren\u2019s syndrome: a systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol Int"},{"key":"2021061821294781800_key363-B164","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren\u2019s syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021061821294781800_key363-B165","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0360-3016(01)01549-8","article-title":"Stage I and II MALT lymphoma: results of treatment with radiotherapy","volume":"50","author":"Tsang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021061821294781800_key363-B166","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1111\/j.1572-0241.1998.00724.x","article-title":"A diffuse T lymphocytic gastrointestinal mucosal infiltration associated with Sjogren\u2019s syndrome resulting in a watery diarrhea syndrome and responsive to immunosuppressive therapy","volume":"93","author":"Sobhani","year":"1998","journal-title":"Am J Gastroenterol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2574\/38695042\/key363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2574\/38695042\/key363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:55:39Z","timestamp":1694019339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/6\/2574\/5321166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":166,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,15]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key363","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2019,2,15]]}}}